<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01433861</url>
  </required_header>
  <id_info>
    <org_study_id>SNUBHGS</org_study_id>
    <nct_id>NCT01433861</nct_id>
  </id_info>
  <brief_title>Laparoscopy-assisted Proximal Gastrectomy Versus and Laparoscopy-assisted Total Gastrectomy</brief_title>
  <acronym>PRAPT</acronym>
  <official_title>Phase III Prospective Randomized Clinical Trial of Laparoscopy-assisted Proximal Gastrectomy (LAPG) and Laparoscopy-assisted Total Gastrectomy (LATG) for Upper Gastric Cancer. (Multicenter Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The choice of surgical strategy for patients with proximal gastric cancer is controversial
      mainly because proximal gastrectomy is infamous for high rates of reflux symptoms and
      anastomotic stricture. but there are no prospective randomized trials until now.

      The primary end point of this study is whether the rate of reflux esophagitis is different or
      not between LAPG and LATG. Through this study, we
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective Randomized Clinical Trials between Laparoscopy-assisted Proximal Gastrectomy and
      Laparoscopy-assisted Total Gastrectomy.

      LAPG reconstruction: double tract reconstruction (3 anastomosis, intracorporeal Roux-en Y
      esophago-jejunostomy, extracorporeal gastro-jejunostomy 10cm below
      esophago-jejunostomy,extracorporeal jejuno-jejunostomy 20cm below gastro-jejunostomy)

      LATG reconstruction: intracorporeal Roux-en Y esophago-jejunostomy

      Primary end point : incidence of reflux esophagitis after operation

      Sample Size : LAPG 97 cases, LATG 97 cases (p1=0.018 p2=0.018, a=0.05, b=0.80)
      Non-inferiority test, non-inferior margin (delta) : 0.05. Sample size calculated by our
      MRCC(Medical Research Collaborating Center, http://mrcc.snubh.org)

      Study duration : 48 months (enrollment 36months, follow-up 12months)

      Reflux esophagitis evaluation methods

        1. Ambulatory 24hr-pH esophageal holter monitoring for acid reflux

        2. DISIDA scan for bile reflux

        3. Endoscopic evaluation (Grading according to LA classification)

        4. Visick score (subjective symptoms)

        5. EORTC sto 22 and GIQLI evaluation (Quality of Life)

        6. Nutritional Benefits (Body weight, Triceps Skin folds Thickness, Blood test)

        7. Upper gastrointestinal study

        8. Gastric emptying scan
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    We planed to study later
  </why_stopped>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of reflux esophagitis</measure>
    <time_frame>postoperative 3 month</time_frame>
    <description>Comprehesive evaulation by 24hr pH monitoring, DISIDA scan, Endoscopic evaluation according to LA classification and Visick score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of reflux esophagitis</measure>
    <time_frame>postoperative 6 month</time_frame>
    <description>Comprehesive evaulation by 24hr pH monitoring, DISIDA scan, Endoscopic evaluation according to LA classification and Visick score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of reflux esophagitis</measure>
    <time_frame>postoperative 12 month</time_frame>
    <description>Comprehesive evaulation by 24hr pH monitoring, DISIDA scan, Endoscopic evaluation according to LA classification and Visick score</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>LAPG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LAPG : laparoscopy-assisted proximal gastrectomy with double tract reconstruction group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LATG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LATG : laparoscopy-assisted total gastrectomy group</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopy-assisted gastrectomy</intervention_name>
    <description>Laparoscopy-assisted proximal gastrectomy versus Laparoscopy-assisted total gastrectomy</description>
    <arm_group_label>LAPG</arm_group_label>
    <arm_group_label>LATG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 20~80

          -  Informed consent

          -  No other malignancies

          -  Proximal gastric cancer met by following conditions

               1. Lesion located on proximal stomach (upper one third)

               2. Lesion below 5cm in size

               3. Lesion confined to proper muscle depth (cT2)

               4. No evidence of metastatic enlarged LN on #5, 6, 4d, 10 basins and other distant
                  metastasis. (cN1)

        Exclusion Criteria:

          -  If patients is only suitable to total gastrectomy, he will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyung-Ho Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyenggi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2011</study_first_submitted>
  <study_first_submitted_qc>September 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2011</study_first_posted>
  <last_update_submitted>January 6, 2017</last_update_submitted>
  <last_update_submitted_qc>January 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Hyung-Ho Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <keyword>proximal gastrectomy</keyword>
  <keyword>total gastrectomy</keyword>
  <keyword>laparoscopy</keyword>
  <keyword>reflux esophagitis</keyword>
  <keyword>double tract reconstruction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

